Camurus

Camurus is a Lund-based pharmaceutical company and one of Skåne's biggest biotech success stories. The company develops and commercializes long-acting medicines based on its proprietary FluidCrystal technology, with a focus on opioid dependence, pain, cancer, and endocrine disorders. Its flagship product Buvidal (buprenorphine long-acting injection) treats opioid use disorder and is used by over 70,000 patients globally. Listed on Nasdaq Stockholm, Camurus reported SEK 2.3 billion in total revenues for 2025 with a profit before tax of SEK 933 million and employs approximately 200 people.